Pasireotide

Pasireotide (SOM230, trade name Signifor) is an orphan drug approved in the U.S. and Europe for the treatment of Cushing's disease and acromegaly in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.